263. Soares J.C., Mallinger A.G. Intracellular phosphatidylinositol pathway abnormalities in bipolar disorder patients. Psychopharmacology Bulletin 1997; 33: 685–691.
264. Sophocles. Ajax. Cambridge University Press, Cambridge, 2001.
265. Starkstein S.E., Robinson R.G. Mechanism of disinhibition after brain lesions. Journal of Nervous and Mental Disease 1997; 185: 108–114.
266. Stevens A., Price J. Evolutionary Psychiatry: A New Beginning. Routledge, London, 1996.
267. Strakowski S.M., Adler C.M., DelBello M.P. Metabolic dysfunction within the anterior limbic network in bipolar disorder: a model for studying new treatments. Neuropsychiatria i Neu-ropsychologia 2006; 1: 5-14.
268. Strong C.M., Nowakowska C., Santosa C.M. et al. Temperament-creativity relationships in mood disorder patients, healthy controls and highly creative individuals. Journal of Affective Disorders 2007; 100: 41–48.
269. Strzyzewski W., Rybakowski J., Chtopocka-Wozniak M., Czerwinski A. Klozapina w leczeniu stanow maniakalnych. Psychiatria Polska 1981; 15: 331–332.
270. Styron W. Darkness Visible. A Memoir of Madness. Vintage Books, Newe York, 1991.
271. Swerdlow N.R., Stephany N, Wasserman LC et al. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl) 2003; 169: 314–320.
272. Szadoczky E., Papp Z., Vitrai J. et al. The prevalence of major depressive and bipolar disorders in Hungary. Results from a national epidemiologic survey. Journal of Affective Disorders 1998; 50: 153–162.
273. Tellenbach H. Melancholie. Problemgeschichte, Endogenität, Typologie, Pathogenese, Klinik. Springer, Berlin, 1961.
274. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971–983.
275. Tohen M., Baker R.W., Altshuler L.L. et al. Olanzapine versus divalproex in the treatment of acute mania. American Journal of Psychiatry 2002; 159: 1011–1017.
276. Tohen M., Chengappa K.N., Suppes T. et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. British Journal of Psychiatry 2004; 184: 337–345.
277. Tohen M., Greil W., Calabrese J.R. et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry 2005; 162: 1281–1290.
278. Tohen M., Vieta E., Calabrese J. et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 2003; 60: 1079–1088.
279. Torrance E.P. Torrance Tests of Creative Thinking. Scholastic Testing Service, Bensenville, Illinois, 1990.
280. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. Journal of Clinical Psychiatry 2005; 66 (Suppl 1): 2429.
281. Vornik L.A., Brown E.S. Management of comorbid bipolar disorder and substance abuse. Journal of Clinical Psychiatry 2006; 67 (Suppl 7): 2430.
282. Weiskrantz L. Behavioral changes associated with ablation of the amygdaloid complex in monkeys. Journal of Comparative Psychology and Physiology 1956; 49: 381–391.
283. Weissman M.M., Leaf P.J., Tischler G.L. et al. Affective disorders in five United States communities. Psychological Medicine 1988; 18: 141–153.
284. Welt L. Über Charakterveränderungen des Menschen infolge von Läsionen des Stirnhirns. Deutsches Archiv für klinische Medizin 1888; 42: 339–390.
285. Weygandt W. Über die Mischzustände des manisch-depressiven Irreseins. JF Lehmann, München, 1899.
286. Whybrow P.C. A Mood Apart. The Thinker’s Guide to Emotion and Its Disorders. Harper Perennial, New York, 1997.
287. Whybrow P.C. American mania. Ciągle więcej, ale nigdy dość. Termedia Wydawnictwo Medyczne, Poznań, 2006.
288. Whybrow P.C. American Mania. When More Is Not Enough. WW Norton & Company, New York – London, 2005.
289. Whybrow P.C, Akiskal H.S, McKinney W.T. Mood Disorders. Toward a New Psychobiology. Plenum Press, New York, 1984.
290. Whybrow P. Bahr R. The Hibernation Response. Arbor House, William Morrow, New York, 1988.
291. Whytt R. Observations on the Nature, Causes, and Cure of Those Disorders which have been Commonly Called Nervous, Hypochondriac, or Hysteric, to which are Prefixed Some Remarks on the Sympathy of the Nerves. T Becket and P DuHondt, London, and J Balfour, Edinburgh, 1765.
292. Wijeratne C., Malhi G.S. Vascular mania: an old concept in danger of sclerosing? A clinical overview. Acta Psychiatrica Scandinavica 2007; 434: 35–40.
293. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292–295.
294. Wilson E.O. On Human Nature. Harvard University Press, Camridge, Massachusets, 2004.
295. Wise L.A, Zierler S., Krieger N., Harlow B.L. Adult onset of major depressive disorder in relation to early life violent victimisation: a case-control study. Lancet 2001; 358: 881–887.
296. Woody E., Claridge G. Psychoticism and thinking. British Journal of Social and Clinical Psychology 1977; 16: 241–248.
297. Wurtzel E. Prozac Nation. Young and Depressed in America. Quartet Books, London, 1996.
298. Zarate C.A. Is clozapine a mood stabilizer? Journal of Clinical Psychiatry 1995; 56: 108112.
299. Zarate C.A. Jr, Singh J.B., Carlson P.J. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006; 63: 856–864.
300. Zarate C.A., Singh J.B., Carlson P.J et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 2007; 9: 561–570.